Martin Picard

Darmstadt, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Journal: Journal of neuro-oncology

Published: June 28, 2017

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

Journal: Oncotarget

Published: January 03, 2016

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 16, 2015

Does cilengitide deserve another chance?-Authors' reply.

Does cilengitide deserve another chance?-Authors' reply.

Journal: The Lancet. Oncology

Published: December 03, 2014

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Journal: Neuro-oncology

Published: September 30, 2014

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology

Published: August 29, 2014

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.

Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.

Journal: Journal of neuro-oncology

Published: October 16, 2013

Integrins as therapeutic targets.

Integrins as therapeutic targets.

Journal: Trends in pharmacological sciences

Published: February 08, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026